🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation NCT05010109NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography, Echocardiography, Exercise Cardiac Stress T… A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site📍 Hangzhou Betta Pharmaceuticals Co., Ltd. · Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8… A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites📍 Birmingham📍 Duarte📍 Boston Taiho Oncology, Inc. · Tests: TAS6417, CYP Cocktail, Transporter Cocktail Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) NCT07761910Phase 21 site📍 Indianapolis Indiana University · Tests: PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites📍 Newport Beach📍 San Diego📍 San Francisco Bayer · Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites📍 Hefei📍 Harbin📍 Wuhan Abbisko Therapeutics Co, Ltd · Tests: ABSK043 in combination with Firmonertinib Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites📍 Sacramento📍 Tampa📍 Tampa National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729Phase 3246 sites📍 Bakersfield📍 Beverly Hills📍 Stamford Merck Sharp & Dohme LLC · Tests: Calderasib, Placebo, Pembrolizumab Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy NCT05468242Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy, Tislelizumab ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy NCT07109531Phase 31 site📍 Shanghai Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Tests: ASKC202+ Limertinib, Pemetrexed + Cisplatin /Carboplatin Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site📍 Nanchang Second Affiliated Hospital of Nanchang University · Tests: Vebreltinib, Furmonertinib 80mg A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site📍 Taipei AP Biosciences Inc. · Tests: AP203, AP203 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) NCT07149649Phase 2, Phase 311 sites📍 Aarau📍 Aarau📍 Baden Swiss Cancer Institute · Tests: Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose, Isotonic saline solution 0.9% Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI NCT06545747Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: DCE-MRI based split-course hypo-RT, CT based split-course hypo-RT, Concurrent chemotherapy, Consolidative immunotherapy Spatial Fragmentation Combined With Low-dose Radiotherapy for Immunotherapy Combined With Chemotherapy-resistant Locally Advanced or Advanced Non-small Cell Lung Cancer NCT06775678Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Spatially Fractionated Radiation Therapy Combined With Low-dose Radiotherapy, Conventional fractionated radiotherapy Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer NCT07008742n/a1 site📍 London Royal Marsden NHS Foundation Trust Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer NCT05168566Phase 231 sites📍 Glendale📍 Washington D.C.📍 Athens Teligene US · Tests: Sutetinib Maleate Capsule Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients NCT04980716Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Multiple cardiovascular drugs related to "Golden Triangle" Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression NCT06749860Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: Disitamab Vedotin + tislelizumab + bevacizumab Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C NCT05631249Phase 25 sites📍 Lyon📍 Marseille📍 Paris Gustave Roussy, Cancer Campus, Grand Paris · Tests: Sotorasib 120Mg Tab A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer NCT04951635Phase 31 site📍 Ji'nan Jiangsu Hansoh Pharmaceutical Co., Ltd. · Tests: Almonertinib, Placebo Almonertinib PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC NCT06102057Phase 211 sites📍 Dresden📍 Essen📍 Freiburg im Breisgau TheraOp · Tests: standard Radiotherapy, Chemotherapy, Immunotherapy, Experimental Radiotherapy Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site📍 Guangzhou Avistone Biotechnology Co., Ltd. · Tests: PLB1004 Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer NCT06865339Phase 21 site📍 The Bronx Montefiore Medical Center · Tests: Cemiplimab, Fianlimab, Radiotherapy, Platinum Doublet Chemotherapy (PDC) D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure NCT06300177Phase 386 sites📍 Hefei📍 Beijing📍 Beijing Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: D-1553 Tablet, Docetaxel injection A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites📍 Springdale📍 Duarte📍 Irvine AbbVie · Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality NCT06496490Phase 225 sites📍 Fuzhou📍 Foshan📍 Guangzhou Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy